Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D2 | Q14995 | 2/20 | 0.85 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17982799 | 0.99 | NR1D1 (0.84) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29378837 | 0.92 | NR1D2 (1.00) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16636446 | 0.92 | NR1D2 (1.00) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29497168 | 0.91 | NR1D2 (0.98) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16638084 | 0.91 | NR1D2 (0.98) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16636902 | 0.91 | NR1D2 (0.98) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16636237 | 0.91 | NR1D1 (0.84) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18021946 | 0.91 | NR1D1 (0.83) | NR1D2NR1D1ALDH1A1BACE1TSHR | |
| Hydrochloric Acid SCHEMBL16637574 | 0.90 | NR1D2 (0.96) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16636389 | 0.90 | NR1D2 (0.96) | NR1D2NR1D1ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055293-B1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-12-06 | — | — | EP | claimed |
| US-9949968-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-04-24 | — | — | US | disclosed |
| US-9949968-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-04-24 | — | — | US | disclosed |
| EP-3055293-B1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-12-06 | — | — | EP | disclosed |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-05-18 | — | — | US | disclosed |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-05-18 | — | — | US | disclosed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-9611245-B2 | Diarylalkylamine REV-ERB antagonists and their use as medicaments | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-04 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2016-08-18 | — | — | US | disclosed |
| EP-3055293-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | Fondazione Istituto Italiano di Tecnologia (IT) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052283-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237057-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | NR1D2 9/4885NR1D1 1/4885ALDH1A1 3689/4885 |
| US-20170136009-A1 | DIARYLALKYLAMINE REV-ERB ANTAGONISTS AND THEIR USE AS MEDICAMENTS | NR1D1, NR1I3, BCOR | NR1D2 9/4885NR1D1 1/4885ALDH1A1 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.